Showing results (1101-1110 of 6,501) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|February 17, 2020
LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer developmentLining Zhou, Yu Tian, Fang Guo, et al.Cancer Immunology, Immunotherapy : CII|February 13, 2020
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytesKenichiro Yahiro, Yoshihiro Matsumoto, Hisakata Yamada, et al.Cancer Immunology, Immunotherapy : CII|February 14, 2020
Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiationFei-Fei Gu, Jing-Jing Wu, Yang-Yang Liu, et al.Cancer Immunology, Immunotherapy : CII|December 8, 2019
CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1Nuray Erin, Sayra Dilmaç, Anna Curry, et al.Cancer Immunology, Immunotherapy : CII|December 8, 2019
Mechanisms of immune evasion in bladder cancerPaul L Crispen, Sergei KusmartsevCancer Immunology, Immunotherapy : CII|January 9, 2020
Role of sensory neurons, neuroimmune pathways, and transient receptor potential vanilloid 1 (TRPV1) channels in a murine model of breast cancer metastasisNuray ErinCancer Immunology, Immunotherapy : CII|January 10, 2020
Long-term surviving cancer patients as a source of therapeutic TCRElse Marit Inderberg, Sébastien WälchliCancer Immunology, Immunotherapy : CII|January 12, 2020
Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancerCaroline Bergenfelz, Anna Roxå, Meliha Mehmeti, et al.Cancer Immunology, Immunotherapy : CII|February 24, 2020
Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor modelJose-Ignacio Rodriguez-Barbosa, Miyuki Azuma, Gennadiy Zelinskyy, et al.Cancer Immunology, Immunotherapy : CII|January 19, 2020
Immune biological rationales for the design of combined radio- and immunotherapiesMichael Hader, Benjamin Frey, Rainer Fietkau, et al.Pageof 651